[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].

Neurologische Klinik, Knappschaftskrankenhaus Bochum-Langendreer, Ruhr-Universität Bochum, In der Schornau 23-25, 44892, Bochum, Deutschland.
Der Schmerz (Impact Factor: 1.5). 03/2008; 22(1):16-23.
Source: PubMed

ABSTRACT The platinum derivative oxaliplatin is widely used in colorectal cancer. Its side effects differ from those of the other platinum compounds cisplatin and carboplatin. An acute, painful hyperexcitability syndrome (HES) accompanied by cold induced paresthesia, dysesthesia and myotonia is unique to oxaliplatin, whereas a chronic, peripheral sensory neuropathy (PSN) can be caused by all platinum compounds. It is believed that HES is the result of peripheral nerve hyperexcitability as a consequence of voltage-gated sodium channel dysfunction, which may be caused by calcium level imbalance. Therapeutic options for HES are the administration of calcium and magnesium, the serotonin and noradrenaline reuptake inhibitor (SNRI) venlafaxine and the thiophosphate amifostine.

  • Source
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Analgesic efficacy varies depending on the pain syndrome being treated. One reason for this may be a differential effect of individual pain syndromes on the function of the endogenous pain control circuits at which these drugs act to produce analgesia. To test this hypothesis, we examined the effects of diverse (i.e., ongoing inflammatory, neuropathic, or chronic widespread) pain syndromes on analgesia induced by activation of an opioid-mediated, noxious stimulus-induced endogenous pain control circuit. This circuit was activated by subdermal capsaicin injection at a site remote from the site of nociceptive testing. Analgesia was not affected by carrageenan-induced inflammatory pain or the early phase of oxaliplatin neuropathy (a complication of cancer chemotherapy). However, the duration of analgesia was markedly shorter in the late phase of oxaliplatin neuropathy and in alcoholic neuropathy. A model of fibromyalgia syndrome produced by chronic unpredictable stress and proinflammatory cytokines also shortened analgesia duration, but so did the same stress alone. Therefore, since chronic pain can activate neuroendocrine stress axes, we tested whether they are involved in the attenuation of analgesic duration induced by these pain syndromes. Rats in which the sympathoadrenal axis was ablated by adrenal medullectomy showed normal duration pain-induced analgesia in groups with either late-phase oxaliplatin neuropathy, alcoholic neuropathy, or exposure to sound stress. These results support the suggestion that pain syndromes can modulate activity in endogenous pain control circuits and that this effect is sympathoadrenal dependent.
    The Journal of Neuroscience : The Official Journal of the Society for Neuroscience 10/2010; 30(41):13699-706. DOI:10.1523/JNEUROSCI.2867-10.2010 · 6.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die Behandlung des metastasierten kolorektalen Karzinoms (KRK) hat sich in den letzten Jahren entscheidend gewandelt und wird zunehmend zur individualisierten Therapie. Seit wenigen Jahren stehen neben einer Reihe von hochwirksamen Chemotherapeutika monoklonale Antikörper für die Behandlung zur Verfügung. Mittlerweile hängt die Entscheidung über die Art und Dauer der Therapie stark davon ab, welches Ausmaß die Erkrankung hat und ob der Patient symptomatisch ist. Auch das Vorliegen bestimmter genetischer Veränderungen beeinflusst die Wahl der Substanz. Therapieziel in der palliativen Situation bleibt die Verlängerung des Überlebens und eine Verbesserung der Lebensqualität. Bei der Patientengruppe, die primär nicht resektable Lebermetastasen aufweist, die durch Verkleinerung resezierbar werden können, kann durch eine intensive neoadjuvante Therapie sekundär die Möglichkeit der chirurgischen Entfernung der Tumormanifestationen herbeigeführt und die Patienten können so potenziell geheilt werden. Treatment of advanced colorectal carcinoma (aCRC) has changed considerably over the past few years and is becoming increasingly individualized. In addition to highly effective chemotherapeutics, monoclonal antibodies became available for treating CRC a few years ago. The decision as to the type and duration of treatment now heavily depends on the extent of the disease and whether the patient is symptomatic. The existence of certain genetic changes also affects the choice of substance. The aim of palliative treatment remains to extend the patient’s life and to improve quality of life. In a patient group with primarily non-resectable liver metastases that may become resectable following a reduction in size, intensive neoadjuvant therapy can create the option of secondary surgical removal of the tumor manifestations and thus potentially cure the patients.
    Der Gastroenterologe 03/2008; 3(2):135-143. DOI:10.1007/s11377-008-0169-y